Intellia Therapeutics
NTLA
11.71
-0.66
-5.34%
Intellia Therapeutics
US · NTLA
#2899 by market cap
Listed 2016
11.71
-0.66
-5.34%
Live - 5344 symbols - heartbeat 373s ago
· 2026-10-08 08:30
Pre-market
11.66
-0.43%
After-hours
11.81
+0.85%
Overnight
11.68
-0.26%
- Market cap
- 1.64B
- P/E (TTM)i
- -3.51
- P/Bi
- 2.25
- EPSi
- -3.81
- Div yieldi
- 0.00%
- 52W posi
- 19%
Reader sentiment
Are you bullish or bearish on NTLA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.9 percentage points.
Institutional ownership
- Held by institutions
- 101.67% -2.86pp
- Institutions
- 385 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund70.74%
Hedge Fund16.94%
Public Company7.17%
VC/PE Fund3.55%
Private Company2.69%
Individual/Insider1.62%
Government Pension Fund0.45%
Family Office/Trust0.13%
Top holders as of 2026-06-30
ARK Investment Management LLC
12.04% · 16.88M sh
BlackRock
11.00% · 15.41M sh
State Street Global Advisors
6.59% · 9.23M sh
Vanguard Portfolio Management, LLC
5.23% · 7.33M sh
Vanguard Capital Management, LLC
4.96% · 6.95M sh
D. E. Shaw & Co., L.P.
4.60% · 6.44M sh
Two Sigma Investments, LP
3.74% · 5.24M sh
FMR
3.40% · 4.76M sh
RA Capital Management, L.P.
3.23% · 4.53M sh
Regeneron Pharmaceuticals, Inc.
2.64% · 3.70M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| John Leonard | Chief Executive Officer | 0.86% |
| Fred Cohen | Independent Director | 0.14% |
| Edward Dulac | Executive Vice President, Chief Financial Officer and Treasurer | 0.11% |
| William Chase | Independent Director | 0.10% |
| Eliana Clark | Executive Vice President | 0.07% |
| David Lebwohl | Chief Medical Officer | 0.06% |
| James Basta | General Counsel | 0.05% |
| Michael Dube | VP, CAO & principal accounting officer | 0.05% |
| Birgit Schultes | Senior VP & Head of Cell Therapies | 0.05% |
| Derek Hicks | Executive VP & Chief Business Officer | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-20 | John Leonard | Chief Executive Officer | Automatic Disposition | -22,675 | $12.60–13.00 |
| 2026-08-19 | John Leonard | Chief Executive Officer | Intent to Sell (Form 144) | -22,675 | $12.95 |
| 2026-07-21 | Edward Dulac | Executive Vice President, Chief Financial Officer and Treasurer | Open Market Disposition | -8,111 | $11.25 |
| 2026-07-01 | Edward Dulac | Executive Vice President, Chief Financial Officer and Treasurer | Automatic Disposition | -4,677 | $18.00 |
| 2026-06-30 | Michael Dube | VP, CAO & principal accounting officer | Open Market Disposition | -2,641 | $16.78 |
| 2026-06-08 | Fred Cohen | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Fred Cohen | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Franciscus A. G. Verwiel | Independent Chairperson | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Franciscus A. G. Verwiel | Independent Chairperson | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | William Chase | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | William Chase | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Brian Goff | Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Brian Goff | Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Jesse Goodman | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Jesse Goodman | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Georgia Keresty | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Georgia Keresty | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-06-08 | Muna Bhanji | Independent Director | Other Acquisition | +9,200 | -- |
| 2026-06-08 | Muna Bhanji | Independent Director | Other Derivative Acquisition | +13,300 | $12.89 |
| 2026-03-01 | James Basta | General Counsel | Open Market Disposition | -1,211 | $13.78 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:30:29 · For reference only, not investment advice and not tailored to your situation.